Published October 7, 2024
Vitrolife: Customer Perspective & Custom Embryo Development Algorithms
inpractise.com/articles/vitrolife-customer-perspective-and-custom-embryo-development-algorithms
Executive Bio
Chief Scientific Officer at IVF Clinic Network
Interview Transcript
Disclaimer: This interview is for informational purposes only and should not be relied upon as a basis for investment decisions. In Practise is an independent publisher and all opinions expressed by guests are solely their own opinions and do not reflect the opinion of In Practise.
This is a snippet of the transcript.to get full access.
Since PGT-A testing, have there been any major scientific developments or improvements to the overall process, would you say?
There's an imaging process every few minutes, allowing us to examine them in great detail without disturbing their protected environment. This has accumulated data that we can mine, helping us understand not just embryo development better, but also which embryos and patterns of development are most associated with a healthy pregnancy. This has resulted in the development of selection algorithms and many research papers studying the nuances of embryo development, which can only be a good thing.
This is a snippet of the transcript.to get full access.
How much of the positive results of time-lapse technology are attributable to the embryo staying undisturbed in the incubator versus the actual data part of it? Which one contributes more? How do you think about that?
We've built our own algorithms to predict birth outcomes because we were first movers in the UK and accumulated a lot of data. In the UK, we are obliged to collect birth outcome data, so our dataset is very complete. We've built and validated these algorithms properly with training and validation datasets and prospectively validated them. We know that it is identifying and ranking the best embryos for us better than we could otherwise.
This is a snippet of the transcript.to get full access.
Are you using images from the EmbryoScope, or do you have a custom incubator or a competitor's device? How does that work? What's the source of the data, so to speak?
We've used the EmbryoScope for many years, and I'd say 90% of our time-lapse devices are EmbryoScope. We've acquired some clinics that have different systems, like the Geri time-lapse incubator. We try to apply our knowledge and learnings from the EmbryoScope to the images and systems from the Geri. It's a challenging exercise, but I believe the human embryo follows a predetermined pathway of development. It doesn't make biological sense that an algorithm built on one image system would be different from another. Technically, there are some challenges in translating, but overall, I think they should be completely compatible.
Free Sample of 50+ Interviews
Sign up to test our content quality with a free sample of 50+ interviews.
Or contact sales for full access
Related Content

Avantor: Post-Pandemic Bioprocessing Competitive Landscape
Former President at Cytiva

AGC Biologics & Western vs Chinese CDMOs
Executive at AGC Biologics

Sartorius: Single Use Support & Danaher's Fluid Management Technology Edge
Former VP of Product Development at Sartorius

Sartorius: Upstream Bioprocessing Market Dominance
Former Senior Product Management Director at Sartorius Stedim Biotech
© 2024 In Practise. All rights reserved. This material is for informational purposes only and should not be considered as investment advice.